Peripheral Modulation of Muscle Stiffness and Spasticity

Muscle Spasticity Clinical Trial

Official title:

Peripheral Modulation of Muscle Stiffness and Spasticity

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03306615
• Other study ID #: IRB00273264
• Status: Recruiting
• Phase: Phase 2
• Start date: October 11, 2021
• Est. completion date: November 16, 2024

Study information

• Verified date: November 2023
• Source: Johns Hopkins University
• Contact: Azin Etemadimanesh, MD
• Phone: 410-955-1347
• Email: aetemad2[@]jhmi.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, double-blind, randomized, placebo-controlled, sequential Phase II trial of human recombinant hyaluronidase injections in individuals with post-stroke upper limb muscle stiffness. The investigators will recruit 50 subjects, 25 males and 25 females, who will be randomized to receive either hyaluronidase plus saline (treatment arm, n=25) or normal saline (control arm, n=25) injections (first injection) in Phase 1 of the study over 5 visits that will test all 3 study aims. Then subjects will join the Phase 2 to receive a second injection, where the treatment arm will receive the placebo and the placebo arm will receive the treatment. It is expected that approximately 50 participants will be enrolled to produce 42 evaluable participants. This design will ensure that all subjects receive the drug treatment, which will facilitate recruitment. The injecting physician, the assessors, and the patients will be blind to group assignment. Randomization will be initiated by the IDS pharmacy as per the study statistician. All patients will be assessed at seven visits over 9 weeks of the study: Visit 1 - screening and baseline assessment of aims 1 and 2 (week 1-2); Visit 2 - pre-injection MRI for aim 3 (week 1-2); Visit 3 - first injection (week 2); Visit 4 - post-injection MRI (week 3-5); Visit 5 - post-injection follow up for aims 1 and 2 (week 3-5); CROSSOVER TO OPPOSITE TREATMENT ARM Visit 6 - Second injection (week 6); Visit 7 - post-injection follow-up for aims 1 and 2/ final study visit (week 7-9). There will be no MRI assessment after the second injection as the technique is adequately sensitive to demonstrate changes with a small sample size. The investigators will follow the patients for approximately 9 weeks in this study. After obtaining informed consent, subjects will be screened to ensure that the subjects meet study criteria.

Description:

1. To test the effect of hyaluronidase injections on upper limb outcomes. The investigators will test the hypothesis that compared to placebo, human recombinant hyaluronidase injections will increase total passive ROM across the affected shoulder, elbow and forearm as measured by motion analysis (primary outcome), isometric muscle strength or force generation capacity using MVC on EMG, reduce upper limb motor impairment as measured by the Fugl-Meyer (FM) scale, and improve function as measured by the Wolf Motor Function Test (WMFT).

2. To evaluate the effect of hyaluronidase on neural and non-neural components of muscle stiffness. The investigators will test the hypothesis that compared to placebo, IM hyaluronidase will modulate the passive and potentially also the active component of the stretch reflex, reduce stiffness and improve arm motor control.

3. To determine the effect of hyaluronidase on intramuscular GAG content. The investigators will test the hypothesis that compared to placebo, IM hyaluronidase will reduce the T1rho relaxation times in the biceps and triceps muscles of the affected arm.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: November 16, 2024
• Est. primary completion date: November 16, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ischemic or hemorrhagic stroke 4-180 months prior

• Moderately-severe muscle stiffness

• Lack of full passive and active range of motion in at least 2/4 areas (shoulder, elbow, forearm, wrist) in the hemiparetic upper limb;

• Willingness to have MRI, complete all clinical assessments, and comply with study protocols;

• Ability to give informed consent and HIPPA certifications; and

Exclusion Criteria:

• treatment of spasticity with Botulinum toxin or intrathecal baclofen within the past six months, phenol injections within the past 12 months, or ongoing adjustment of anti-spastic medications;

• other neurologic condition that may affect motor response (e.g., Parkinson's disease, ALS, MS);

• clinically significant cognitive dysfunction with score <19 on Folstein's Mini Mental Status Examination or depression with score >10 on the PHQ-9;

• pregnancy;

• known hypersensitivity to hyaluronidase;

• claustrophobia;

• standard contraindications for MRI

• Any condition that will preclude the patient from completing the protocol as determined by the PI

Related Conditions & MeSH terms

• Muscle Spasticity

Intervention

Drug:
• Hyaluronidase
HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
• Placebo
0.9% Sodium Chloride Injection

Locations

Country	Name	City	State
United States	Paria Arfa Fatollahkhani, MD, M.Sc.	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total upper limb passive range of motion	passive range of motion in shoulder, elbow and forearm joints	9 weeks
Secondary	Total upper limb active range of motion	active range of motion in shoulder, elbow and forearm joints	9 weeks
Secondary	Change in upper limb Fugl-Meyer Assessment Score	measures motor impairment in the affected upper limb, Score range is 0-66, and a higher score indicates a better outcome	9 weeks
Secondary	Change in Wolf-Motor Function Test (WMFT) Score	Measures upper extremity function following stroke, Includes 6 items, with a 0-5 score range for each item, and a higher score indicates a better outcome	9 weeks